The Pulmonary Hypertension Association (PHA) provides this tool to help participants learn more about research ongoing in PH. Use the filters below to narrow the search results to fit your personal needs. Each listing describes current research, who qualifies to participate, and whom to contact for information.
No personal information can be collected through this tool. The information presented on the PHA Clinical Trials page has been obtained directly from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH). PHA recommends that you use the information in this resource to begin a conversation with your PH specialist about whether or not participating in research is right for you.
This is a prospective, longitudinal, observational study of free-living activity trackers and
patient reported outcomes to test the hypothesis that daily activity will have stronger
prognostic value than 6MWD in patients with pulmonary hypertension after 12 weeks.
This study is a prospective, non-randomized, two arm, single-center acute feasibility study
assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH
In this prospective study, the investigators will implement a systematic assessment of
adherence to diuretics in a cohort of patients with precapillary pulmonary hypertension.
This study is designed to:
- determine the overall adherence rates for diuretic regimen
- determine the determinants of non-adherence to diuretics
- assess the risk of PH worsening occurrence in the non-adhesion group
The investigators intend to evalute the value of radiomics signature of pulmonary vessels
from chest computed tomography (CT) for dianosis and prognosis of pulmonary arterial
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored
trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these
trials until lack of patient benefit as assessed by investigator, or commercial availability
This study is being conducted to assess the long-term safety, tolerability, and efficacy of
sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial
Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data
from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in
hemodynamic and functional improvements in the study participants, including those receiving
maximal PAH therapy with double/triple drug combinations and intravenous prostacyclin.
The primary objective of this open-label, LTFU study is to evaluate the long-term safety and
There is a lack of effective treatments for chronic obstructive pulmonary disease (COPD)
complicated with pulmonary hypertension. Previous studies have found that inhaled nitric
oxide (iNO) can reduce pulmonary artery pressure and improve exercise capacity in COPD with
pulmonary hypertension patients. However, the specific mechanism is unclear. The study aims
to evaluate pulmonary ventilation/perfusion, pulmonary artery pressure, oxygenation, symptoms
and quality of life in COPD with pulmonary hypertension patients after short-term treatment
with iNO. Observing a series of pathophysiological changes caused by the treatment of
The primary purpose of the study is to evaluate the safety and tolerability of the long-term
use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202
(NCT05147805) and other lead-in studies of TPIP in participants with PAH.
The primary objective of this study is to evaluate the safety and tolerability of the
long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and
other lead-in studies of TPIP in participants with PH-ILD.
This is a prospective, single-arm, single-center, explorative clinical trial to evaluate the
effect of Rituximab on disease progression in subjects with SLE-PAH receiving concurrent
stable-dose standard medical therapy. The study will focus on assessment of clinical response
and safety measures longitudinally. In addition, the biomarker of treatment efficacy with
Rituximab and pathogenic autoantibody response in this disease will be investigated.